Eagle Pharmaceuticals Inc (EGRX) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $1.28 (+696.65%), Market cap $0.00B, P/E ratio 2.50, 52-week low–high $0.00 ~ $3.74.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3
Financial statements, price targets, institutional (13F) holdings and related news for Eagle Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Eagle Pharmaceuticals Inc trades at $1.28 (+696.65%). Real-time quotes and charts are available on BlackAll Trade.
Eagle Pharmaceuticals Inc has a market cap of about $0.00B. Its P/E ratio is 2.50.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical